Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05197049 · ClinicalTrials.gov registry record · Phase 3
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
A Phase 3 study of Crohn Disease, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT05197049: Active Phase 3 study of Crohn Disease, sponsored by Janssen Research & Development.
NCT05197049 is a Phase 3 study of Crohn Disease that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 350 participants, above the 201-participant average among 71 other Crohn Disease trials with a reported enrollment target (74% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05197049, a Phase 3 study of Crohn Disease, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
Primary Outcome
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score \<150. The multi-item CDAI score assessed severity of illness by collecting information on 8 different Crohn's disease-related variables (extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid or very soft stools, abdominal pain/cramps, and general well-being). The last 3 variables were scored over 7 days by the participant on a diary ca
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Guselkumab Dose 1
- DRUG Guselkumab Dose 2
- DRUG Guselkumab Dose 3
Study Locations (20)
California
- Om Research LLC - Lancaster
- United Gastroenterologists - Los Alamitos
- Paul Wallace MD - Los Angeles
- Clinnova Research - Orange
- Digestive System Healthcare - Pasadena
- Northshore Gastroenterology Research, LLC - San Diego
- Clinical Applications Laboratories, Inc - San Diego
- Santa Maria Gastroenterology - Santa Maria
- Clinical Research of California - Walnut Creek
Florida
- Gastroenterology Associates of SW Florida - Clearwater
- Pioneer Research Solutions Inc. - Coconut Creek
- Omega Research Consultants - DeBary
- Harmony Medical Research Institute, Inc. - Hialeah
Arizona
- Advanced Gastro P.C - Chandler
- Reliance Research - Scottsdale
Arkansas
- Moore Clinical Trials, LLC - Little Rock
- Central Arkansas Veterans Healthcare System - Little Rock
Alabama
- Digestive Health Specialists of the Southeast - Dothan
Colorado
- Amel Med LLC Research - Grand Junction
Connecticut
- Western Connecticut Health Network/Danbury Hospital - Danbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2022-01-19 |
| Est. Completion | 2028-10-30 |
| Phase | Phase 3 |
What the registry record for NCT05197049 still lists
NCT05197049 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 201-participant average among 71 other Crohn Disease trials with a reported enrollment target (74% higher).
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05197049 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05197049 about?
NCT05197049 is a clinical study titled "A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease". The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
What is the current status of trial NCT05197049?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2022-01-19. Estimated completion is 2028-10-30.
What conditions does trial NCT05197049 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT05197049?
The interventions under investigation include: Placebo (DRUG), Guselkumab Dose 1 (DRUG), Guselkumab Dose 2 (DRUG), Guselkumab Dose 3 (DRUG).
Who is sponsoring clinical trial NCT05197049?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05197049 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05197049's enrollment target sits among peer trials
350 10th of 71 higher than 62 of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RECRUITING · Phase 3
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
COMPLETED · Phase 3
-
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
COMPLETED · Phase 3
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI